The Phosphoinositide 3-kinase (PI3K) pathway is at the core of multiple fundamental biological processes controlling metabolism, protein synthesis, cell growth, survival, and migration. This inevitably leads to the involvement of...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PI3K/SIGNAL-CANCER
Roles of Class I PI 3 kinase isoforms in signalling and canc...
178K€
Cerrado
PI3K-C2-SIG
Signalling mechanisms of the class II isoforms of PI 3 kinas...
231K€
Cerrado
PID2019-106937RB-I00
HIF2 & NFE2L2, UNA APROXIMACION RACIONAL Y OTRA IMPARCIAL PA...
278K€
Cerrado
SAF2010-21019
FUNCION DE LA ISOFORMA BETA DE PI3K EN FISIOLOGIA Y PATOLOGI...
526K€
Cerrado
PID2021-128119OA-I00
VIAS DE SEÑALIZACION CELULAR QUE DETERMINAN RESPUESTAS A INH...
168K€
Cerrado
BFU2011-30303
ESTUDIO DEL EFECTO DE NOLINEALIDADES EN REDES DURANTE LA RES...
114K€
Cerrado
Información proyecto Phd
Duración del proyecto: 50 meses
Fecha Inicio: 2015-08-07
Fecha Fin: 2019-10-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The Phosphoinositide 3-kinase (PI3K) pathway is at the core of multiple fundamental biological processes controlling metabolism, protein synthesis, cell growth, survival, and migration. This inevitably leads to the involvement of the PI3K signalling pathway in a number of different diseases, ranging from inflammation and diabetes to cancer, with PI3K pathway alterations present in almost 80% of human cancers. Therefore, PI3Ks have emerged as important targets for drug discovery and, during 2014, the first PI3K inhibitor was approved by FDA in the US for the treatment of a lymphocytic leukaemia. Nonetheless, our understanding of PI3K-mediated signalling is still poor and only a fraction of the potential therapeutic applications have been addressed so far, leaving a large amount of translational work unexplored. Europe features a set of top quality research institutions and pharmaceutical companies focused on PI3K studies but their activities have been so far scattered. This proposal fills this gap by providing a multidisciplinary network (biochemistry, mouse studies, disease models, drug development, software development) and an unprecedented training opportunity from the bench to the bedside (from pre-clinical discoveries to clinical trials), through cutting edge molecular biology, drug discovery and clinical trial organization. The proposal is aimed at training young investigators in deep understanding of the different PI3K isoforms in distinct tissues and to translate this knowledge into a new generation of PI3K inhibitors, treatment modalities and into identify new uses for existing PI3K inhibitors.